Iron-induced hypophosphatemia: An emerging complication

Current Opinion in Nephrology and Hypertension

Volumn 26, Issue 4, 2017, Pages 266-275

  Zoller, Heinz ^a   Schaefer, Benedikt ^a   Glodny, Bernhard ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

hypophosphatemia; iron; osteomalacia

Indexed keywords

IRON; PHOSPHATE; IRON DERIVATIVE;

CLINICAL FEATURE; DRUG INDUCED DISEASE; HUMAN; HYPOPHOSPHATEMIA; IRON INDUCED HYPOPHOSPHATEMIA; NONHUMAN; PATHOPHYSIOLOGY; PHOSPHATE METABOLISM; PRIORITY JOURNAL; REVIEW; RISK FACTOR; CHEMICALLY INDUCED; FRACTURE; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; OSTEOMALACIA;

ADMINISTRATION, INTRAVENOUS; FRACTURES, BONE; HUMANS; HYPOPHOSPHATEMIA; IRON COMPOUNDS; OSTEOMALACIA;

EID: 85017460615     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000329     Document Type: Review

References (67)

1. Okada M, Imamura K, Fuchigami T, et al. [2 cases of nonspecific multiple ulcers of the small intestine associated with osteomalacia caused by longterm intravenous administration of saccharated ferric oxide]. Nihon Naika Gakkai zasshi 1982; 71: 1566-1572.
2. Schouten BJ, Doogue MP, Soule SG, Hunt PJ. Iron polymaltose-induced fgf23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem 2009; 46 (Pt 2): 167-169.
3. Mani LY, Nseir G, Venetz JP, Pascual M. Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient. Transplantation 2010; 90: 804-805.
4. Van Wyck DB, Mangione A, Morrison J, et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009; 49: 2719-2728.
5. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of fgf23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98: 6500-6505.
6. Sabbagh Y, Giral H, Caldas Y, et al. Intestinal phosphate transport. Adv Chronic Kidney Dis 2011; 18: 85-90.
7. Saito H, Kusano K, Kinosaki M, et al. Human fibroblast growth factor-23 mutants suppress na-dependent phosphate co-transport activity and 1alpha, 25-dihydroxyVitamin d3 production. J Biol Chem 2003; 278: 2206-2211.
8. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001; 276: 7811-7819.
9. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093.
10. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093.
11. Shayeghi M, Latunde-Dada GO, Oakhill JS, et al. Identification of an intestinal heme transporter. Cell 2005; 122: 789-801.
12. Qiu A, Jansen M, Sakaris A, et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell 2006; 127: 917-928.
13. McKie AT, Barrow D, Latunde-Dada GO, et al. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 2001; 291: 1755-1759.
14. Gunshin H, Mackenzie B, Berger UV, et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997; 388: 482-488.
15. Donovan A, Brownlie A, Zhou Y, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000; 403: 776-781.
16. Finch C. Regulators of iron balance in humans. Blood 1994; 84: 1697-1702.
17. Wolf M, White KE. Coupling fibroblast growth factor 23 production and cleavage: Iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens 2014; 23: 411-419.
18. Econs MJ, McEnery PT. Autosomal dominant hypophosphatemic rickets/ osteomalacia: Clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 1997; 82: 674-681.
19. Imel EA, Peacock M, Gray AK, et al. Iron modifies plasma fgf23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 2011; 96: 3541-3549.
20. Kapelari K, Kohle J, Kotzot D, Hogler W. Iron supplementation associated with loss of phenotype in autosomal dominant hypophosphatemic rickets. J Clin Endocrinol Metab 2015; 100: 3388-3392.
21. David V, Martin A, Isakova T, et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 2016; 89: 135-146.
22. Farrow EG, Yu X, Summers LJ, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (adhr) phenotype in fibroblast growth factor-23 (fgf23) knock-in mice. Proc Natl Acad Sci USA 2011; 108: E1146-1155.
23. Benet-Pages A, Lorenz-Depiereux B, Zischka H, et al. Fgf23 is processed by proprotein convertases but not by phex. Bone 2004; 35: 455-462.
24. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 2013; 28: 1793-1803.
25. Bager P, Hvas CL, Dahlerup JF. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. Br J Clin Pharmacol 2016. [Epub ahead of print]
26. Schaefer B, Wurtinger P, Finkenstedt A, et al. Choice of high-dose intravenous iron preparation determines hypophosphatemia risk. PLoS One 2016; 11: e0167146
27. Malone M, Barish C, He A, Bregman D. Comparative review of the safety and efficacy of ferric carboxymaltose versus standard medical care for the treatment of iron deficiency anemia in bariatric and gastric surgery patients. Obes Surg 2013; 23: 1413-1420.
28. Toxicity grading scale: (2005). http: //www. fda. gov/downloads/Biologics BloodVaccines/ucm091977.
29. Shiraki M. [metabolic bone diseases: osteomalacia due to fe or al poisoning]. Nihon Rinsho 1986; 44: 2493-2498.
30. Sato K, Shiraki M. Saccharated ferric oxide-induced osteomalacia in japan: iron-induced osteopathy due to nephropathy. Endocr J 1998; 45: 431-439.
31. Suzuki A, Ohoike H, Matsuoka Y, Irimajiri S. Iatrogenic osteomalacia caused by intravenous administration of saccharated ferric oxide. Am J Hematol 1993; 43: 75-76.
32. Konjiki O, Fukaya S, Kanou H, et al. [a case of hypophosphatemia induced by intravenous administration of saccharated iron oxide]. Nihon Ronen Igakkai Zasshi 1994; 31: 805-810.
33. Sato K, Nohtomi K, Demura H, et al. Saccharated ferric oxide (sfo)-induced osteomalacia: In vitro inhibition by sfo of bone formation and 1, 25-dihydroxyVitamin d production in renal tubules. Bone 1997; 21: 57-64.
34. Shimizu Y, Tada Y, Yamauchi M, et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide. Bone 2009; 45: 814-816.
35. Yamamoto S, Okada Y, Mori H, et al. Iatrogenic osteomalacia: report of two cases. J UOEH 2013; 35: 25-31.
36. Moore KL, Kildahl-Andersen O, Kildahl-Andersen R, Tjonnfjord GE. Uncommon adverse effect of a common medication. Tidsskr Nor Laegeforen 2013; 133: 165.
37. Blazevic A, Hunze J, Boots JM. Severe hypophosphataemia after intravenous iron administration. Netherlands J Med 2014; 72: 49-53.
38. Fierz YC, Kenmeni R, Gonthier A, et al. Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient. Eur J Clin Nutr 2014; 68: 531-533.
39. Vandemergel X, Vandergheynst F. Potentially life-threatening phosphate diabetes induced by ferric carboxymaltose injection: a case report and review of the literature. Case Rep Endocrinol 2014; 2014: 843689.
40. Barea Mendoza JA, Gredilla Zubiria I, Gonzalez Olmedo J, Mateo Alvarez S. [hypophosphatemia, a poorly known adverse reaction of intravenous use of iron]. Med Clin 2014; 143: 284-285.
41. Poursac N. Hypophosphatë mie et fgf23 ë levë. Rhumatos 2015; 12: 61-64.
42. Sangros Sahun MJ, Goni Girones E, Camarero Salazar A, et al. Symptomatic hypophosphataemic osteomalacia secondary to the treatment with iron carboxymaltose detected in bone scintigraphy. Rev Esp Med Nucl Imagen Mol 2016; 35: 391-393.
43. Schaefer B, Glodny B, Zoller H. Loosing blood and bone. Gastroenterology 2017; 152:. [Epub ahead of print]
44. Bacchetta J, Salusky IB. Evaluation of hypophosphatemia: lessons from patients with genetic disorders. Am J Kidney Dis 2012; 59: 152-159.
45. Haglin L. Using phosphate supplementation to reverse hypophosphatemia and phosphate depletion in neurological disease and disturbance. Nutr Neurosci 2016; 19: 213-223.
46. Elder CJ, Bishop NJ. Rickets. Lancet 2014; 383: 1665-1676.
47. Gonciulea AR, Jan De Beur SM. Fibroblast growth factor 23-mediated bone disease. Endocrinol Metab Clin North Am 2017; 46: 19-39.
48. Phan CM, Guglielmi G. Metabolic bone disease in patients with malabsorption. Semin Musculoskelet Radiol 2016; 20: 369-375.
49. Amanzadeh J, Reilly RF Jr. Hypophosphatemia: an evidence-based approach to its clinical consequences and management. Nat Clin Pract Nephrol 2006; 2: 136-148.
50. Fukumoto S. Phosphate metabolism and Vitamin d. BoneKEy reports 2014; 3: 497.
51. Endo I, Fukumoto S, Ozono K, et al. Clinical usefulness of measurement of fibroblast growth factor 23 (fgf23) in hypophosphatemic patients: proposal of diagnostic criteria using fgf23 measurement. Bone 2008; 42: 1235-1239.
52. Hautmann AH, Hautmann MG, Kolbl O, et al. Tumor-induced osteomalacia: an up-to-date review. Curr Rheumatol Rep 2015; 17: 512.
53. Onken JE, Bregman DB, Harrington RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: The repair-ida trial. Nephrol Dial Transplant 2014; 29: 833-842.
54. Onken JE, Bregman DB, Harrington RA, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion 2014; 54: 306-315.
55. Derman R, Roman E, Modiano MR, et al. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol 2017; 92: 286-291.
56. Bhandari S, Kalra PA, Kothari J, et al. A randomized, open-label trial of iron isomaltoside 1000 (monofer(r)) compared with iron sucrose (venofer(r)) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant 2015; 30: 1577-1589.
57. Johansson PI, Rasmussen AS, Thomsen LL. Intravenous iron isomaltoside 1000 (monofer(r)) reduces postoperative anaemia in preoperatively nonanaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a. Vox Sang 2015; 109: 257-266.
58. Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in nondialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant 2016; 31: 646-655.
59. Birgegard G, Henry D, Glaspy J, et al. A randomized noninferiority trial of intravenous iron isomaltoside versus oral iron sulfate in patients with nonmyeloid malignancies and anemia receiving chemotherapy: the profound trial. Pharmacotherapy 2016; 36: 402-414.
60. Reinisch W, Staun M, Tandon RK, et al. A randomized, open-label, noninferiority study of intravenous iron isomaltoside 1, 000 (monofer) compared with oral iron for treatment of anemia in ibd (proceed). Am J Gastroenterol 2013; 108: 1877-1888.
61. Charytan C, Bernardo MV, Koch TA, et al. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multicenter study. Nephrol Dial Transplant 2013; 28: 953-964.
62. Qunibi WY, Martinez C, Smith M, et al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of nondialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011; 26: 1599-1607.
63. Geerse DA, Bindels AJ, Kuiper MA, et al. Treatment of hypophosphatemia in the intensive care unit: a review. Crit Care 2010; 14: R147.
64. Felsenfeld AJ, Levine BS. Approach to treatment of hypophosphatemia. Am J Kidney Dis 2012; 60: 655-661.
65. Linglart A, Biosse-Duplan M, Briot K, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect 2014; 3: R13-30.
66. Sutton RA, Mumm S, Coburn SP, et al. Atypical femoral fractures' during bisphosphonate exposure in adult hypophosphatasia. J Bone Miner Res 2012; 27: 987-994.
67. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the american society for bone and mineral research. J Bone Miner Res 2014; 29: 1-23.